Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Pancreatic Neoplasms 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 112Cisplatin 76Oxaliplatin 44pembrolizumab 34Fluorouracil 32Capecitabine 30durvalumab 27Leucovorin 26lenvatinib 23Magnetic Resonance Spectroscopy 15Irinotecan 14Nivolumab 12Biopsy 12Albumin-Bound Paclitaxel 12tislelizumab 11Specimen Handling 11Radiofrequency Ablation 11Drug Therapy 11pemigatinib 10apatinib 10Taxes 10Floxuridine 10130-nm albumin-bound paclitaxel 10Radiotherapy 9Bevacizumab 9Platinum 8Folfox protocol 8Carboplatin 81,2-diaminocyclohexaneplatinum II citrate 8tremelimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Cholangiocarcinoma × merestinib × Clear all
NCT03027284 2020-05-19

A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

Eli Lilly and Company

Phase 1 Completed
19 enrolled
GastrointestinalLymphoid

Gallbladder Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡